News - Tidingo.com

Once-Daily VYVANSE(R) Significantly Improved ADHD Symptoms In One Of The Largest Controlled Stimulant Trials In Adults With ADHD

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published in the September issue of the Journal of Clinical Psychiatry found once-daily VYVANSE significantly improved Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults within the first week of treatment.

Worst - 1

1
2
3
4
5

Best - 5

07.10.2008 18:00:00 - Health News from Medical News Today

Hard link

Company To Sequence 1,000 Human Genomes In 2009 For $5,000 Each

Complete Genomics Inc., a third-generation human genome sequencing company, has announced its formal launch as the world's first provider of large-scale human genome sequencing services. The company, which was established in March 2006, has been operating in "stealth mode" from a 32,000-square-foot facility near San Francisco.

Worst - 1

1
2
3
4
5

Best - 5

07.10.2008 18:00:00 - Health News from Medical News Today

Hard link

Scalp Psoriasis - Dermipsor Signs Strategic Drug Development Collaboration With VA Boston Research Institute, Inc

Dermipsor Ltd, a clinical-stage leading drug development company focusing on novel therapies for the dermatology market, announces signing a Cooperative Research and Development Agreement with the VA Boston Research Institute, Inc. Under the terms of the Cooperative Research and Development Agreement this collaborations framework covers the advancement of Phase 2 and Phase 3 clinical trials.

Worst - 1

1
2
3
4
5

Best - 5

07.10.2008 18:00:00 - Health News from Medical News Today

Hard link

In Mouse Model Of Premature Aging Disorder Anti-cancer Drug Prevents, Reverses Cardiovascular Damage

Â An experimental anti-cancer drug can prevent -- and even reverse -- potentially fatal cardiovascular damage in a mouse model of progeria, a rare genetic disorder that causes the most dramatic form of human premature aging, National Institutes of Health (NIH) researchers reported today.

Worst - 1

1
2
3
4
5

Best - 5

07.10.2008 18:00:00 - Health News from Medical News Today

Hard link

Rifaximin Demonstrates Highly Statistically Significant Results In Prevention Of Hepatic Encephalopathy In Pivotal Phase 3 Study

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the successful completion and outcome of its pivotal Phase 3 trial to evaluate the efficacy, safety and tolerability of rifaximin in preventing hepatic encephalopathy, or HE.

Worst - 1

1
2
3
4
5

Best - 5

07.10.2008 18:00:00 - Health News from Medical News Today

Hard link

SLC2A9 Is A High-Capacity Urate Transporter In Humans, Discovered By Researchers

An international team of researchers led by Professors Mark Caulfield and Patricia Munroe, from the William Harvey Research Institute at Barts and The London School of Medicine and Dentistry with Chris Cheeseman at the University of Alberta in Canada and Kelle Moley at the University of Washington in

Worst - 1

1
2
3
4
5

Best - 5

07.10.2008 18:00:00 - Health News from Medical News Today

Hard link

ImClone Announces Merger Agreement With Eli Lilly At $70 Per Share

ImClone Systems Incorporated (NASDAQ: IMCL) announced today that it has entered into a merger agreement with Eli Lilly and Company (NYSE: LLY), pursuant to which Lilly has agreed to commence a tender offer for no less than a majority of the issued and outstanding shares of ImClone common stock at a net price per share of $70 in cash.

Worst - 1

1
2
3
4
5

Best - 5

07.10.2008 18:00:00 - Health News from Medical News Today

Hard link

Brazilian Acai Berry Antioxidants Absorbed By Human Body

A Brazilian palm berry, popular health food though little research has been done on it, now may have its purported benefits better understood. In the first research involving people, the acai (ah-sigh-EE) berry has proven its ability to be absorbed in the human body when consumed both as juice and pulp.

Worst - 1

1
2
3
4
5

Best - 5

07.10.2008 18:00:00 - Health News from Medical News Today

Hard link

Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization From Health Canada For Treatment Of Multiple Myeloma

Celgene International Sarl (NASDAQ: CELG) announced that its oral cancer drug REVLIMID (lenalidomide) has received marketing authorization approval from Health Canada for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. Multiple myeloma is the second most commonly diagnosed blood cancer worldwide.

Worst - 1

1
2
3
4
5

Best - 5

07.10.2008 18:00:00 - Health News from Medical News Today

Hard link

Publication Of Implementation Of Breast Health Guidelines For Developing Countries

A special supplement of the Oct. 15 journal Cancer for the first time details guidelines for low- and middle-income countries to implement breast cancer programs to detect and treat the most common disease among women worldwide.

Worst - 1

1
2
3
4
5

Best - 5

07.10.2008 18:00:00 - Health News from Medical News Today

Health News from Medical News Today

Once-Daily VYVANSE(R) Significantly Improved ADHD Symptoms In One Of The Largest Controlled Stimulant Trials In Adults With ADHD

Company To Sequence 1,000 Human Genomes In 2009 For $5,000 Each

Scalp Psoriasis - Dermipsor Signs Strategic Drug Development Collaboration With VA Boston Research Institute, Inc

In Mouse Model Of Premature Aging Disorder Anti-cancer Drug Prevents, Reverses Cardiovascular Damage

Rifaximin Demonstrates Highly Statistically Significant Results In Prevention Of Hepatic Encephalopathy In Pivotal Phase 3 Study

SLC2A9 Is A High-Capacity Urate Transporter In Humans, Discovered By Researchers

ImClone Announces Merger Agreement With Eli Lilly At $70 Per Share

Brazilian Acai Berry Antioxidants Absorbed By Human Body

Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization From Health Canada For Treatment Of Multiple Myeloma

Publication Of Implementation Of Breast Health Guidelines For Developing Countries

RSS sources

Your own sources

Public sources